Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001415889-25-004410
Filing Date
2025-02-18
Accepted
2025-02-18 16:22:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 15163
2 JOINT FILING AGREEMENT ex-99-02182025_090236.htm EX-99.1 2333
  Complete submission text file 0001415889-25-004410.txt   19191
Mailing Address 2884 SAND HILL ROAD SUITE 100 MENLO PARK CA 94025
Business Address 2884 SAND HILL ROAD SUITE 100 MENLO PARK CA 94025 212-909-3022
Enavate Sciences GP, LLC (Filed by) CIK: 0001953107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D

Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Subject) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-94871 | Film No.: 25635239
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)